A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial design, targeted patient selection, and real-world evidence to speed label expansion.
Alan Baldridge, MD
Advertisement
Senior Director, Gastroenterology and Hepatology, Drug Development Solutions, ICON
Articles by Alan Baldridge, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny
2
ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy
3
Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif
4
Clinical Site Readiness for Cell and Gene Therapies: Operational and Supply Chain Challenges as they Scale and as they Expand into the Community Care Setting
5